Advances in antimicrobial therapy of community-acquired pneumonia

Current Opinion in Infectious Diseases

Volumn 12, Issue 2, 1999, Pages 137-143

  Mandell, Lionel A ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001662572     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199904000-00006     Document Type: Article

References (72)

1. Mandell LA, Niederman M. The Canadian community-acquired pneumonia consensus conference group: antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4:25-28.
2. Niederman MS, Bass JB, Campbell GD, Fein AM, Grossman RF, Mandell LA. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. 1993; 148:1418-1426.
3. Bartlett, JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26:811-838.
4. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985; 78:45-51.
5. National Center for Health Statistics. National hospital discharge survey: annual summary 1990. Vital Health Stat 1992; 13:1-225. Excellent review of issues involved in site of care decisions.
6. Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Infect Dis Clin North Am 1998; 12:741-759.
7. Mandell LA, Loeb M. Microbiology of hospital-acquired pneumonia. Semin Respir Crit Care Med 1997; 18:111-120.
8. Bartlett JG, O'Keefe P, Talley F, Louie TJ, Gorbach SL, et al. Bacteriology of hospital-acquired pneumonia. Arch Intern Med 1986; 146:868-871.
9. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69:307-316.
10. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18:501-515.
11. Marston BJ, Plouffe JF, File Jr TM, Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157:1709-1718.
12. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankly SS, Weissfeld, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996; 275:143-141.
13. Berntsson E, Lagergard T, Strannegard O, Trollfors B, et al. Etiology of community-acquired pneumonia in outpatients. Eur J Clin Microbiol 1996; 5:446.
14. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101:508.
15. Erard PH, Moser F, Wenger A, Saghafi L, Bille J, Francioli P, et al. Prospective study on community-acquired pneumonia diagnosed and followed up by private practitioners. CHUV, Lausanne, Switzerland. Abstracts of the 31st ICAAC, Chicago, IL, October 1991. Abstract 56.
16. Langille DB, Yates L, Marrie TJ. Serological investigation of pneumonia as it presents to the physician's office. Can J Infect Dis 1993; 4:328-332.
17. Moine P, Vercken J-B, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia: etiology, epidemiology and prognostic factors. Chest 1994; 105:1487-1495.
18. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia: etiology, prognosis and treatment. Am Rev Respir Dis 1990; 142:369-373.
19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S5 supplement, vol 24, no 16. Villanova, PA: National Committee for Laboratory Standards; 1994.
20. Doern GV, Brueggemann A, Holley Jr HP, Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40:1208-1213.
21. Einarsson S, Kristjansson M, Kristinsson K, Kjartansson G, Johnsson S. Pneumonia cause by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scand J Infect Dis 1998; 30:253-256.
22. Klugman KP, Feldman C. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia. Infect Dis Clin Pract 1998; 7:180-184.
23. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-480. This paper is often referred to and is worth reading. Very good study of pneumonia in Barcelona.
24. Plouffe JF, Breiman RF, Facklam RR for the Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. JAMA 1996; 275:194-198.
25. Wise R, Brenwald N, Gill M, Fraise A. Streptococcus pneumoniae resistance to fluoroquinolones [Letter]. Lancet 1996; 348:1660. Important letter regarding resistance to quinolones.
26. Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier JM, Beaucaire G. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intens Care Med 1995; 21:24-31.
27. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterial. J Antimicrob Chemother 1994; 33:685-706.
28. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42:410-425.
29. Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother 1997; 40:205-211.
30. Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Gruneberg RN. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997; 39 (Suppl. B):43-39.
31. Biedenbach DJ, Jones RN. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn Microbiol Infect Dis 1996; 25:47-51.
32. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41:478-480.
33. Shonekan D, Handwerger S, Mildvan D. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother 1997; 39:405-409.
34. Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, Cl-960 and Cl-990. J Antimicrob Chemother 1993; 31:505-522.
35. Wiedemann B, Heisig P. Antibacterial activity of grepafloxacin. J Antimicrob Chemother 1997; 40 (Suppl. A): 19-25.
36. Wise R, Andres JM. The activity of grepafloxacin against respiratory pathogens in the UK. J Antimicrob Chemother 1997; 40 (Suppl. A):27-30.
37. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and - resistant pneumococci [Letter]. J Antimicrob Chemother 1995; 35:230-232.
38. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997; 41:1818-1824.
39. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41:101-106.
40. Rolston KVI, Ho DH, Leblanc B, Streeter H, Dvorak T. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J Antimicrob Chemother 1997; 39 (Suppl. B): 15-22.
41. Hoska M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992; 36:2108-2117.
42. Wise R, Brenwald NP, Andrews JM, Boswell F. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. J Antimicrob Chemother 1997; 39:447-452.
43. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother 1997; 41:2312-2316.
44. Aldridge KE, Ashcraft D, Bowman KA. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob Agents Chemother 1997; 41:484-487.
45. Nord CE. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin Infect Dis 1996; 23 (Suppl. 1):S15-S18.
46. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994; 38:2471-2476.
47. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41:709-711.
48. Goldstein EJC, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, Cl-960, Cl-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992; 36:1158-1162.
49. Appelbaum PC. Quinolone activity against anaerobes: microbiological aspects. Drugs 1995; 49 (Suppl. 2):76-60.
50. Hecht DW, Wexler HM. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis 1996; 23 (Suppl. 1)S2-S8.
51. Miyashita N, Niki Y, Kishimoto T, Nakajima M, Matsushima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997; 41:1331-1334.
52. Waites KB, Duffy LB, Schmid T, Crabb D, Pate MS, Cassell GH. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to parfloxacin and PD 127391. Antimicrob Agents Chemother 1991; 35:1181-1185.
53. Ridgway GL, Salman H, Robbins MJ, Dencer C, Felmingham D. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother 1997; 40 (Suppl. A):31-34.
54. Edelstein PH, Edelstein MAC, Lehr KH, Ren J. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996; 37:117-126.
55. Kaku M, Ishida K, Irifune K et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994; 38:738-741.
56. Roblin PM, Hammerschlag MR. Activity of BAY 12-8039, a new 8-methoxyquinolone, against Chlamydia pneumoniae in vitro (Abstract F011). In: Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans: American Society for Microbiology; 1996:101.
57. Roblin PM, Jutline A, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997; 41:2033-2034.
58. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996; 40:1048-1049.
59. Craig, WA. Pharmacokinetic/pharmacodynamic parameters. Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
60. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998; 27:33-39.
61. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990; 11:319-326.
62. Blaser J, Stone BB, Groner M, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-1060.
63. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159:281-292.
64. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-490.
65. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81.
66. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. JAMA 1995; 279:125-129.
67. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Resp J 1995; 8:1999-2007.
68. Ørtqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C, and the Scandinavian Sparfloxacin Study Group. Oral empiric treatment of community-acquired pneumonia. Chest 1996; 110:1499-1506.
69. Portier H, May T, Proust A, and the French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996; 37 (Suppl. A):83-91.
70. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB, and the Sparfloxacin European Study Group. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998; 26:1312-1320.
71. O'Doherty B, Dutchman DA, Pettie R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40 (Suppl. A):73-81.
72. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrobia 1997; 41:1965-1972.